Philip S. Boonstra

philbXumichYedu, where X= @ and Y= .
Twitter: @psboonstra
GitHub: psboonstra
Cross Validated: psboonstra
Research Associate Professor,
Dept. of Biostatistics, University of Michigan

Curriculum Vitae

Main   Education   Teaching   Research   Software   Clinical Trials

Clinical Trials (Completed)
  1. Open-label, single-center phase II study of MLN9708 (ixazomib) in patients with relapsed/refractory cutaneous and peripheral T-cell lymphomas
    2.   PI: R Wilcox
      Manuscript
Clinical Trials (Active / Approved)
  1. A phase II pilot study of metformin therapy in patients with relapsed chronic lymphocytic leukemia and untreated CLL patients with genomic deletion 11q
    2.   PI: S Malek
  2. A pilot study of ruxolitinib in secondary hemophagocytic syndrome
    3.   PI: R Wilcox
  3. Phase I dose escalation study to determine the maximum tolerated dose of the combination of ruxolitinib and bortezomib in patients with relapsed or refractory lymphoma
    4.   PI: T Phillips
  4. A phase I/II study of ruxolitinib in combination with nilotinib in patients with chronic phase CML who have achieved a major molecular remission but not a complete molecular remission on a tyrosine kinase inhibitor alone
    5.   PI: P Burke
  5. Phase I multi-site study evaluating the MTD, safety and efficacy of the combination venetoclax, lenalidomide and rituximab in patients with previously untreated mantle cell lymphoma
    6.   PI: T Phillips
  6. Phase I/II study of ixazomib and romidepsin in relapsed/refractory peripheral T-cell lymphoma (PTCL)
    7.   PI: S Devata
  7. Phase Ib, open label, single center study of Pacritinib in relapsed/refractory lymphoproliferative disorders
    8.   PI: R Wilcox
  8. Phase II multi-center single arm study evaluating the effect of adding bortezomib to ibrutinib in ibrutinib relapsed mantle cell lymphoma
    9.   PI: T Phillips
  9. Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
    10.   PI: R Wilcox
  10. Phase 2 study with minimal residual disease (MRD) driven adaptive strategy in treatment for newly diagnosed multiple myeloma with upfront daratumumab-based therapy
    11.   PI: C Ye
  11. A phase II study using a BFM regimen plus tyrosine kinase inhibitor in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
    12.   PI: P Burke
  12. Phase IB dose de-escalation study of the PI3k alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma LYM17-145
    13.   PI: T Phillips

Clinical Trials (Under Review)
  1. Phase II, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms   PI: R Wilcox

Last updated: 23 Apr 2021